Page last updated: 2024-12-06
trestolone
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
trestolone: structure given in first source; RN given refers to (7alpha,17beta)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 9838899 |
| CHEMBL ID | 5197302 |
| SCHEMBL ID | 223290 |
| MeSH ID | M0178178 |
Synonyms (40)
| Synonym |
|---|
| trestolonum [inn-latin] |
| trestolone [inn] |
| estr-4-en-3-one, 17-hydroxy-7-methyl-, (7alpha,17beta)- |
| 19-nor-methyltestosterone |
| estr-4-en-3-one, 17beta-hydroxy-7alpha-methyl- |
| ru 27333 |
| 7alpha-methylnandrolone |
| trestolona [inn-spanish] |
| 7alpha-methyl-3-oxo-4-estren-17beta-ol |
| 17beta-hydroxy-7alpha-methylestr-4-en-3-one |
| 7alpha-methyl-19-nortestosterone |
| nsc 142229 |
| 7alpha-methyl-17beta-hydroxy-4-estren-3-one |
| 17beta-hydroxy-7alpha-methylestr-4-enone |
| 19-nor-7alpha-methyltestosterone |
| 3764-87-2 |
| trestolone |
| ment |
| trestolona |
| unii-40p3287i94 |
| 40p3287i94 , |
| trestolonum |
| 17.beta.-hydroxy-7.alpha.-methylestr-4-en-3-one |
| SCHEMBL223290 |
| DB05830 |
| (7alpha,17beta)-17-hydroxy-7-methylestr-4-en-3-one |
| YSGQGNQWBLYHPE-CFUSNLFHSA-N |
| 17beta-hydroxy-7alpha-methyl-estr-4-en-3-one |
| HY-101734 |
| CS-6648 |
| CHEMBL5197302 , |
| 4-estren-7alpha-methyl-17-beta-ol-3-one |
| (7r,8r,9s,10r,13s,14s,17s)-17-hydroxy-7,13-dimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3(2h)-one |
| DTXSID20863270 |
| Q7838854 |
| A904528 |
| 7-alpha-methyl nortestosterone |
| 4-estren-7-alpha-methyl-17-beta-ol-3-one |
| (1s,3as,3br,4r,9ar,9bs,11as)-1-hydroxy-4,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,5h,7h,8h,9h,9ah,9bh,10h,11h,11ah-cyclopenta[a]phenanthren-7-one |
| bdbm50594908 |
Research Excerpts
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| " Following the demonstration of the safety of MENT Ac in subchronic toxicity studies in rats and rabbits, a pharmacokinetic study was performed in men." | ( Pharmacokinetics of 7 alpha-methyl-19-nortestosterone in men and cynomolgus monkeys. Aguillaume, C; Bardin, CW; Kumar, N; Lähteenmaki, P; Sundaram, K; Suvisaari, J; Tsong, YY, ) | 0.13 |
Compound-Compound Interactions
| Excerpt | Reference | Relevance |
|---|---|---|
| " This study aimed to investigate MENT implants in combination with etonogestrel on spermatogenesis, gonadotropins, and androgen-dependent tissues in comparison with a testosterone/etonogestrel regimen." | ( 7alpha-methyl-19-nortestosterone (MENT) vs testosterone in combination with etonogestrel implants for spermatogenic suppression in healthy men. Anderson, RA; Baird, DT; Kumar, N; Ludlow, H; Walton, MJ, ) | 0.13 |
| " Herein, using transactivation assays, we examined the ability of MENT alone or combined with several 19-nor-derived synthetic progestins to activate androgen receptor (AR)-dependent gene transcription." | ( Comparison of 7α-methyl-19-nortestosterone effectiveness alone or combined with progestins on androgen receptor mediated-transactivation. Chávez, B; Cooney, AJ; García-Becerra, R; Larrea, F; Noé, G; Ordaz-Rosado, D, 2012) | 0.38 |
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| " Since we anticipate using MENT acetate (MENT Ac) rather than MENT as the form of this androgen in humans, the bioavailability of MENT following the administration of MENT and MENT Ac was investigated in cynomolgus monkeys." | ( Pharmacokinetics of 7 alpha-methyl-19-nortestosterone in men and cynomolgus monkeys. Aguillaume, C; Bardin, CW; Kumar, N; Lähteenmaki, P; Sundaram, K; Suvisaari, J; Tsong, YY, ) | 0.13 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " In normal men, a single intravenous bolus of 500 micrograms of MENT led to peak serum MENT levels at 3 minutes after dosing (when the first samples were collected), followed by an exponential decline, reaching undetectable levels by 180 minutes." | ( Pharmacokinetics of 7 alpha-methyl-19-nortestosterone in men and cynomolgus monkeys. Aguillaume, C; Bardin, CW; Kumar, N; Lähteenmaki, P; Sundaram, K; Suvisaari, J; Tsong, YY, ) | 0.13 |
| " In castrated monkeys, dose-response relationships were generated for the effects of testosterone and MENT on gonadotropin levels, prostate growth, body weight, and lipid metabolism." | ( Prostate-sparing effects in primates of the potent androgen 7alpha-methyl-19-nortestosterone: a potential alternative to testosterone for androgen replacement and male contraception. Bardin, CW; Bremner, WJ; Cummings, DE; Kumar, N; Sundaram, K, 1998) | 0.3 |
| " At a dosage of 80 mg twice daily, plasma testosterone levels are largely in the normal range, but plasma DHT tends to be elevated." | ( Androgen replacement therapy: present and future. Bunck, MC; Gooren, LJ, 2004) | 0.32 |
| "The objective of this study was to determine whether the rabbit was a suitable model to test new synthetic androgens for potential liver toxicity within a short dosing interval." | ( Effects of synthetic androgens on liver function using the rabbit as a model. Attardi, BJ; Hild, SA; Koduri, S; Reel, JR; Till, BA, ) | 0.13 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (1)
Activation Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Androgen receptor | Homo sapiens (human) | EC50 (µMol) | 0.0092 | 0.0000 | 0.2079 | 4.3000 | AID1872308 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (56)
Molecular Functions (23)
Ceullar Components (8)
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| plasma membrane | Androgen receptor | Homo sapiens (human) |
| nucleus | Androgen receptor | Homo sapiens (human) |
| nucleoplasm | Androgen receptor | Homo sapiens (human) |
| cytoplasm | Androgen receptor | Homo sapiens (human) |
| cytosol | Androgen receptor | Homo sapiens (human) |
| nuclear speck | Androgen receptor | Homo sapiens (human) |
| chromatin | Androgen receptor | Homo sapiens (human) |
| protein-containing complex | Androgen receptor | Homo sapiens (human) |
| nucleus | Androgen receptor | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
Bioassays (1)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1872308 | Modulation of Androgen receptor (unknown origin) | 2022 | European journal of medicinal chemistry, Feb-15, Volume: 230 | Overview of the development of selective androgen receptor modulators (SARMs) as pharmacological treatment for osteoporosis (1998-2021). |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (32)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (3.13) | 18.7374 |
| 1990's | 17 (53.13) | 18.2507 |
| 2000's | 7 (21.88) | 29.6817 |
| 2010's | 5 (15.63) | 24.3611 |
| 2020's | 2 (6.25) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 3 (8.33%) | 5.53% |
| Reviews | 6 (16.67%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 27 (75.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||